Ensign Peak Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.6M | Hold |
48,399
| – | – | 0.03% | 383 |
|
|
2025
Q1 | $16M | Buy |
48,399
+13,038
| +37% | +$4.32M | 0.03% | 347 |
|
|
2024
Q4 | $10.9M | Buy |
35,361
+19,627
| +125% | +$6.06M | 0.02% | 450 |
|
|
2024
Q3 | $3.34M | Sell |
15,734
-67,639
| -81% | -$14.4M | 0.01% | 763 |
|
|
2024
Q2 | $23.4M | Sell |
83,373
-8,845
| -10% | -$2.48M | 0.04% | 290 |
|
|
2024
Q1 | $24.6M | Buy |
92,218
+30,806
| +50% | +$8.23M | 0.05% | 284 |
|
|
2023
Q4 | $14.2M | Buy |
61,412
+10,365
| +20% | +$2.4M | 0.03% | 356 |
|
|
2023
Q3 | $7.45M | Buy |
51,047
+9,850
| +24% | +$1.44M | 0.02% | 465 |
|
|
2023
Q2 | $9.52M | Buy |
41,197
+13,421
| +48% | +$3.1M | 0.02% | 426 |
|
|
2023
Q1 | $6.73M | Buy |
+27,776
| New | +$6.73M | 0.01% | 492 |
|
|
2022
Q4 | – | Sell |
-4,580
| Closed | -$298K | – | 2039 |
|
|
2022
Q3 | $298K | Sell |
4,580
-8,508
| -65% | -$554K | ﹤0.01% | 1707 |
|
|
2022
Q2 | $937K | Buy |
13,088
+11,528
| +739% | +$825K | ﹤0.01% | 1141 |
|
|
2022
Q1 | $153K | Hold |
1,560
| – | – | ﹤0.01% | 1947 |
|
|
2021
Q4 | $132K | Buy |
+1,560
| New | +$132K | ﹤0.01% | 2011 |
|